Comparative Study of the Therapy of Solar Lentigines With a Q-switched Rubin Laser Versus a Bleaching Cream
Launched by UNIVERSITY OF ZURICH · May 30, 2014
Trial Information
Current as of May 07, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 50
- • female patient must be in post-menopause (\> 2 years)
- • Clinically and dermoscopic confirmed solar lentigines on both sides back of the hands
- Exclusion Criteria:
- • non melanocytic pigmentation, vitiligo, melanoma and suspicion of melanoma
- • intolerance against an ingredience of pigmanorm® cream
- • acute inflammation or eczema on back of the hands
- • patients with renal disease
- • intake of photosensibilisating medication in the past 3 months
- • treatment of solar lentigines on back of the hands in the past 6 months
- • solarium or sun exposure about 6 weeks before and after treatment
- • immunsuppressed patients
About University Of Zurich
The University of Zurich, a leading institution in research and education, is dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. With a robust framework for conducting high-quality research, the university collaborates with multidisciplinary teams of experts to explore cutting-edge therapeutic approaches and interventions. Its commitment to ethical standards and patient safety ensures that all clinical trials are conducted with the utmost integrity, aiming to contribute valuable insights to the medical community and enhance health outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zurich, , Switzerland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials